TALEN-Mediated Gene Editing of HBG in Human Hematopoietic Stem Cells Leads to Therapeutic Fetal Hemoglobin Induction

Christopher T. Lux, David J. Rawlings(Center for Infectious Disease Research), Kyle Jacoby, Mason P. Berger, Julia Yang(Bluebird Bio (United States)), Olivier Humbert(Fred Hutch Cancer Center), Irwin D. Bernstein(Fred Hutch Cancer Center), Olivier Nègre(Inserm), Hans‐Peter Kiem(Fred Hutch Cancer Center), Andrew M. Scharenberg(CTI BioPharma (Italy)), Calvin Lee(Bluebird Bio (United States)), Cynthia Nourigat(Fred Hutch Cancer Center), David Flowers(City Of Hope National Medical Center), Sowmya Pattabhi
Molecular Therapy — Methods & Clinical Development
December 31, 2018
10.1016/j.omtm.2018.12.008
Cited by 51

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
LTRPC7 is a Mg·ATP-regulated divalent cation channel required for cell viability
|Nature|2001|931
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
|Journal of Clinical Oncology|2001|898
ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology
|Nature|2001|897